Navigating Treatment Sequencing in Advanced HR+/HER2− Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies

Dana P. Narvaez, David W. Cescon

Open source

DOI
10.3390/ijms262110366
Published
2025-10-24
Container
International Journal of Molecular Sciences
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/ijms262110366,
  title = {Navigating Treatment Sequencing in Advanced HR+/HER2− Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies},
  author = {Dana P. Narvaez and David W. Cescon},
  year = {2025},
  journal = {International Journal of Molecular Sciences},
  doi = {10.3390/ijms262110366},
  url = {https://doi.org/10.3390/ijms262110366}
}

RIS

TY  - JOUR
TI  - Navigating Treatment Sequencing in Advanced HR+/HER2− Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies
AU  - Dana P. Narvaez
AU  - David W. Cescon
PY  - 2025
JO  - International Journal of Molecular Sciences
DO  - 10.3390/ijms262110366
UR  - https://doi.org/10.3390/ijms262110366
ER  - 

APA

Narvaez, D. P., & Cescon, D. W. (2025). Navigating Treatment Sequencing in Advanced HR+/HER2− Breast Cancer After CDK4/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262110366

Source records